241 related articles for article (PubMed ID: 35849783)
1. Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer.
Schalck A; Sakellariou-Thompson D; Forget MA; Sei E; Hughes TG; Reuben A; Bai S; Hu M; Kumar T; Hurd MW; Katz MHG; Tzeng CD; Pant S; Javle M; Fogelman DR; Maitra A; Haymaker CL; Kim MP; Navin NE; Bernatchez C
Cancer Discov; 2022 Oct; 12(10):2330-2349. PubMed ID: 35849783
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Infiltrating B- and T-Cell Repertoire in Pancreatic Cancer Associated With Host and Tumor Features.
Pineda S; López de Maturana E; Yu K; Ravoor A; Wood I; Malats N; Sirota M
Front Immunol; 2021; 12():730746. PubMed ID: 34630409
[TBL] [Abstract][Full Text] [Related]
3. The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC).
Lianyuan T; Dianrong X; Chunhui Y; Zhaolai M; Bin J
Cancer Biol Ther; 2018 Apr; 19(4):296-305. PubMed ID: 29313457
[TBL] [Abstract][Full Text] [Related]
4. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
5. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
6. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
7. Poor clinical outcomes and immunoevasive contexture in CD161
Chen Q; Yin H; Jiang Z; He T; Xie Y; Mao W; Han J; Liu S; Lou W; Wu W; Habib JR; Yu J; Liu L; Pu N
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38531664
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Amaria R; Knisely A; Vining D; Kopetz S; Overman MJ; Javle M; Antonoff MB; Tzeng CD; Wolff RA; Pant S; Lito K; Rangel K; Fellman B; Yuan Y; Lu KH; Sakellariou-Thompson D; Haymaker CL; Forget MA; Hwu P; Bernatchez C; Jazaeri AA
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309721
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
10. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
[TBL] [Abstract][Full Text] [Related]
11. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
12. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
13. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
14. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.
Hall M; Liu H; Malafa M; Centeno B; Hodul PJ; Pimiento J; Pilon-Thomas S; Sarnaik AA
J Immunother Cancer; 2016; 4():61. PubMed ID: 27777771
[TBL] [Abstract][Full Text] [Related]
15. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
[TBL] [Abstract][Full Text] [Related]
16. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma.
Peng J; Sun BF; Chen CY; Zhou JY; Chen YS; Chen H; Liu L; Huang D; Jiang J; Cui GS; Yang Y; Wang W; Guo D; Dai M; Guo J; Zhang T; Liao Q; Liu Y; Zhao YL; Han DL; Zhao Y; Yang YG; Wu W
Cell Res; 2019 Sep; 29(9):725-738. PubMed ID: 31273297
[TBL] [Abstract][Full Text] [Related]
17. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
[TBL] [Abstract][Full Text] [Related]
18. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression.
Alam MS; Gaida MM; Bergmann F; Lasitschka F; Giese T; Giese NA; Hackert T; Hinz U; Hussain SP; Kozlov SV; Ashwell JD
Nat Med; 2015 Nov; 21(11):1337-43. PubMed ID: 26479921
[TBL] [Abstract][Full Text] [Related]
20. Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC.
Wang J; Zhang T; Li P; Gai J; Chen S; Espinoza G; Kung HC; Zhang R; Fujiwara K; Fu J; Yu J; Zheng L
Cancer Lett; 2023 Oct; 573():216366. PubMed ID: 37640197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]